6523RN Nijmegen, nl
Ypke van Oosterhout
Xenikos to participate in BIO-Europe Spring(R) 2017 - 11th Annual International Partnering Conference
Company to discuss its proprietary immunotherapy T-GuardTM with potential pharmaceutical partners
"We are making good progress with our promising product candidate T-Guard. We are planning to present data from our Phase 1b/2 trial in acute graft versus host disease later this year," said Ypke van Oosterhout, Chief Executive Officer of Xenikos. "In parallel, we are preparing to initiate the Phase 2 trial that is expected to start by the end of the year. In the meantime, we're addressing a request from investigators to reopen the Phase 1b/2 study in a simplified form to enable the treatment of patients with severe acute GVHD until the start of the Phase 2 study. Given all this, we believe this is the perfect time for partnering discussions. We are very much looking forward to evaluate further development opportunities as we strongly believe that our innovative approach can significantly improve the outcome of allogeneic blood stem cell transplantation and help restore patients' health and save lives."
Companies interested in meeting with Xenikos at BIO-Europe Spring 2017 are asked to request a meeting through the event's partneringONE(R) online system or to contact Ypke van Oosterhout directly at email@example.com.
In addition, the Company will also be available to the media for interviews and background discussions.
About BIO-Europe Spring(R)
BIO-Europe Spring is a major springtime partnering conference for the global biotechnology industry serving as a leading international networking platform for decision makers and experts in biotech, pharma and finance. BIO-Europe Spring 2017's program features workshops, plenary discussions, evening networking receptions, presentations and one-on-one meetings and is expected to draw over 2,400 attendees from over 45 countries.
T-Guard is currently in development for the treatment of acute graft versus host disease (GVHD), a life-threatening immune condition. T-Guard consists of a combination of two toxin-loaded anti-T-cell antibodies and shows promise as a therapeutic tool for safely and swiftly resetting the body's immune system in T-cell-mediated diseases. Once injected into the body, T-Guard specifically identifies and eliminates adult T-cells, with a strong preference for the activated ones. The particular combination of immunotoxins used to construct T-Guard was designed to provide a unique blend of synergistic efficacy, narrow specificity and multiple, gentle mechanisms of action. In preclinical testing, T-Guard was shown to be highly effective in killing activated T-cells and to act through apoptotic (programmed cell death) mechanisms, which are associated with minimal side effects. T-Guard's targeted action is believed to leave patients less vulnerable to opportunistic infections when compared to historical controls of institutional standard of care. In a clinical proof-of-concept study, T-Guard appeared to be well tolerated with strong biological and clinical responses observed. T-Guard has completed the clinical Phase 1b/2 testing in Europe for the second-line treatment of steroid-resistant acute GVHD. The primary endpoint of the study is response rate at 28 days. Other endpoints include overall survival at 180 days; safety and tolerability are also being evaluated. Preliminary results from this study showed strong clinical responses and indicated a substantial improvement over published institutional historical survival rates, with a well-manageable side effect profile without severe infusion reactions. T-Guard has been granted Orphan Drug Designation in both the EU and US. The Company plans to initiate a pivotal clinical study in the second half of 2017. Other areas of future development may include transplant-related rejection, acute solid-organ rejection and several severe autoimmune diseases.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to firstname.lastname@example.org.